Table 4.
Indication | Baseline n (%) | Midpoint n (%) | Endpoint N (%) |
---|---|---|---|
Lower respiratory tract infections | 9 (40.9) | 4 (19) | 3 (14.3) |
Lower urinary tract infection | 4 (18.2) | 2 (9.5) | 4 (19) |
Skin and soft tissue infection | 4 (18.2) | 3 (14.3) | 2 (9.5) |
Sepsis | 2 (9.1) | 1 (4.8) | 4 (19) |
Central nervous system infections | 1 (4.5) | 2 (9.5) | 1 (4.8) |
Gastrointestinal infections | 1 (4.5) | 3 (14.3) | 1 (4.8) |
Upper urinary tract infections | 1 (4.5) | 2 (9.5) | 3 (14.3) |
Obstetric/gynaecological infections | 0 | 2 (9.5) | 1 (4.8) |
Ear, nose and throat infections | 0 | 1 (4.8) | 1 (4.8) |
Bone/joint infections | 0 | 1 (4.8) | 0 |
Bronchitis | 0 | 0 | 1 (4.8) |